Navigation Links
Isolagen, Inc. Receives Notification Letter from American Stock Exchange
Date:3/13/2008

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) today announced that on March 12, 2008 it received notice from the American Stock Exchange (AMEX) advising the Company that it does not meet certain of the continued listing standards as set forth in Part 10 of the AMEX Company Guide.

AMEX notified the Company that it was not in compliance with Sections 1003 (a)(i)-(iii) of the AMEX Company Guide. Specifically, the AMEX staff noted that the Company's stockholder's equity was less than $2,000,000 and losses from continuing operations and net losses were incurred in two out of its three most recent fiscal years; that the Company's stockholder's equity was less than $4,000,000 and losses from continuing operations and/or net losses were incurred in three out of its four most recent fiscal years; and that the Company's stockholder's equity was less than $6,000,000 and losses from continuing operations and/or net losses were incurred in its five most recent fiscal years. However, AMEX will not normally consider suspending dealings in the securities of a company which is below any of the above standards if the company (a) has a market capitalization of at least $50,000,000, and (b) has at least 1,100,000 shares publicly held, with a market value of publicly held shares of at least $15,000,000 and 400 round lot shareholders. Isolagen does not currently meet these market capitalization amounts.

In order to maintain its listing, the Company intends to submit a plan to AMEX by April 14, 2008 that will outline the Company's strategy to bring itself back into compliance by September 14, 2009. If the Company's plan to regain compliance is accepted by AMEX, the Company may be able to continue its listing during t
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Isolagen, Inc. Postpones Annual Meeting
2. Capital BlueCross Receives Prestigious Brand Excellence Award From The Blue Cross & Blue Shield Association
3. Highmark Receives Prestigious Brand Excellence Award
4. US Script Receives URAC Pharmacy Benefit Management Accreditation
5. Project Concern International Receives a US$1 Million Grant From the Starbucks Foundations Ethos Water Fund to Provide Safe Water and Sanitation Services in Tanzania
6. Omnilux New-U(TM) Hand-Held Device Receives FDA Approval
7. Sutter Regional Medical Foundation Receives ACR Accreditation
8. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
9. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Cadient Group Receives Multiple Nominations for 2008 DTC National Advertising Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...ndustry pertaining to Lycopene supplements. In a l...nistration to American Longevity (AL), the FDA// d...r lycopene, tomatoes, and tomatoes-based foods con...sed health claims say lycopene (tomatoes, tomato-b...
...f California are finding out a new theory on the f...ignals which connect other brain regions forming a... a sheet of around 10 billion neurons divided into...particular aspects of sensation, movement and cogn...
...ives while over 3,000 people were suffering from t... government officer said Friday//. "Nearly 3,000 t...rafnagar blocks in Surguja district have been in t...gion has reported 10 deaths during the past three ...
...roblems haunting India over the past decade. The p...recorded as many as 459 AIDS related deaths over t...creened during the period between January//, 2002 ...e detected in the state. Furthermore, 641 persons ...
Other Medicine News:Health News:Scientists breaking theory of cortex formation 2Health News:Orissa found to be worst affected by the killer disease, AIDS 2
(Date:10/6/2008)...E Therapy is More Likely to Induce Steroid-Free ...rd Immunomodulator, Azathiopri...esented for the first time,from the Phase 3b Study...odulators and Biologic Therapy (SONIC) may provide...s with moderate to severe Crohn,s disease.,Accordi...
(Date:10/6/2008)...Oct. 6 /- Complete,Genomics Inc., a n...ncing,company, and the Institute for Systems Biolo...uct populationwide human genome studies., In phas...ts proprietary,DNA sequencing technology to sequen..., once proof-of-concept has been demonstrated, ISB...
(Date:10/6/2008)...d for 9:00 AM ET Today -, SEATTLE, Oct. 6 /PRNews...NDN) announced today that it has completed the pla...double-blind, placebo-controlled IMPACT,(IMmunothe...nown as D9902B),clinical trial designed to assess ...ive cellular immunotherapy PROVENGE(R) (sipuleucel...
(Date:10/6/2008)...6 Weeks of Radiation Therapy -, Event: Watch Singl...sday, October 22, 2008, 3 - 4 p.m. by visiting ...Va., Oct. 6 / Questions raced through...st cancer in May. Would she have the,tumor removed...otherapy?, , To view the Multimedia News Release...
Breaking Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections 4037 1FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections 4037 2Pharmacopeia to Receive 245 Million Payment from GlaxoSmithKline 4034 1Pharmacopeia to Receive 245 Million Payment from GlaxoSmithKline 4034 2Pharmacopeia to Receive 245 Million Payment from GlaxoSmithKline 4034 3Pharmacopeia to Receive 245 Million Payment from GlaxoSmithKline 4034 4DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 1DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 2TAX ALERT 3A Deductions for Long Term Care Insurance Premiums 14532 1TAX ALERT 3A Deductions for Long Term Care Insurance Premiums 14532 2
...wswire/ -- D-Pharm announced,today that the result...ompound DP-b99 in the treatment of acute ischemic,...Stroke,Conference. The data will be presented by t...C. Diener, on Thursday May 31st at,14.30 in the Ca...enter in Glasgow. The abstract for the presentatio...
... and on three investigational,agents (VEGF Trap, S...nual ASCO meeting, BRIDGEWATER, N.J., May 29, 2007...d today that a total of 375 abstracts,indicative o...he,43rd Annual Meeting of the American Society of ...e 1-5, 2007). The results from key,studies involvi...
Other Medicine Technology:DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 2DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
Basic-level interpretive resting ECG
Mid-level interpretive resting ECG
Cruise Control is a device developed by STAAR as a filter between the phaco handpiece and aspiration tubing that captures nuclear material, enhances the safety and efficiency of phaco procedures by e
...rovides the ultimate flexibility for performing sl... a patient room or in the sleep laboratory. Travel...an VISION analysis software as your in-lab studies...f many powerful Sleepscan features such as the VIS...
Medicine Products: